Aggregation-induced emission material with multiphoton absorption property as well as preparation method and application of aggregation-induced emission material
By aggregating and induced luminescent molecules based on pyrazine [2,3-g]quinoxaline structural unit, the problems of complex structure and insufficient absorption cross-section of existing materials are solved, and high absorption and high quantum yields are achieved The effect is suitable for multiphoton fluorescence imaging.
Patent Information
- Application Number
- CN202410966785.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-07-18
AI Technical Summary
The existing aggregation-induced luminescent materials have complex structures and are difficult to achieve large-scale synthesis. There is a lack of materials with high absorption cross-section and high fluorescence quantum yield, making it difficult to meet the needs of the biomedical field.
Based on the structural unit of pyrazine [2,3-g]quinoxaline, aggregation-induced luminescent molecules with multiphoton absorption properties were constructed. A simple synthesis method was used to prepare strong molecules with specific reaction steps using triphenylamine as electron donor. Compounds with internal charge transfer characteristics.
It achieves high absorption and high quantum yield in the wavelength range of 400-700nm, displays good photodynamic activity, has the characteristics of simple structure, easy to modify, and adjustable performance, and is suitable for multi-photon fluorescence imaging.
Smart Images

Figure CN119019405A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of aggregation-induced luminescence materials, and in particular relates to a preparation method and application of an aggregation-induced luminescence material with multi-photon absorption properties. Background Art
[0002] Aggregation-induced emission (AIE) molecules have the advantages of excellent photobleaching resistance, biocompatibility and high emission intensity, which can fundamentally solve the aggregation-induced quenching (ACQ) problem of traditional organic fluorescent molecules. The rise of AIE fluorescent materials has provided new options for analytical detection, bioimaging and other fields, especially AIE fluorescent materials with multiphoton absorption properties. The specific identification of bioactive analytes is not only very interesting but also challenging.
[0003] Multiphoton imaging technology has achieved remarkable results in the biomedical field due to its advantages such as high spatial resolution, high penetration depth, low invasiveness, and inherent optical tomography capabilities.
[0004] At present, although many aggregation-induced emission materials with excellent effects have been screened out, their structures are often complex and difficult to synthesize on a large scale, which makes it difficult to meet the requirements of later and clinical trials.
[0005] Therefore, it is of great theoretical and practical significance to continue exploring and screening new aggregation-induced emission materials that have both high absorption cross-sections and high fluorescence quantum yields, simple synthesis methods, and relatively low prices. Summary of the invention
[0006] The first object of the present invention is to provide a series of aggregation-induced luminescence materials with multi-photon absorption properties. The compounds based on the pyrazine [2,3-g] quinoxaline structural unit have the advantages of simple structure, easy modification, adjustable performance, easy preparation, and very high quantum yield under light.
[0007] The second object of the present invention is to provide a method for preparing the above compound.
[0008] The third object of the present invention is to provide the use of the above compound in fluorescence imaging.
[0009] In order to achieve the first invention object, the present invention adopts the following technical solution:
[0010] An aggregation-induced luminescence material having multi-photon absorption properties, wherein the structural formula of the aggregation-induced luminescence material is as shown in Formula I or Formula II:
[0011]
[0012] Wherein, R1 and R2 are independently expressed as:
[0013]
[0014] In the present invention, an aggregation-induced luminescent molecule with multi-photon absorption properties is constructed based on the pyrazine [2,3-g] quinoxaline structural unit, and the molecule has a strong intramolecular charge transfer characteristic. Triphenylamine as an electron donor has a large absorption cross section, so that the material has the property of multi-photon absorption. Among them, "[2,3-g]" represents the connection mode of the quinoxaline ring and the pyrazine ring, that is, the 2nd position of quinoxaline is connected to the 3rd position of pyrazine to form a bridge structure.
[0015] As a preferred technical solution, in the aggregation-induced emission material, R1 and R2 are each independently represented by:
[0016]
[0017] In a second aspect, a method for preparing the compound of formula I described in the first aspect, wherein R1 is The R2 is The preparation method comprises the following steps:
[0018] The second intermediate is mixed with ethanol and dichloromethane, glyoxal is added under stirring, and reflux treatment is performed in an inert gas atmosphere to obtain a reaction mixture; the structural formula of the second intermediate is
[0019]
[0020] Neutralizing the acetic acid in the reaction mixture, and performing an extraction operation with an extractant to obtain an organic phase;
[0021] The solvent in the organic phase is removed to obtain compound PQ-L1; the structural formula of the compound PQ-L1 is:
[0022]
[0023] As a preferred technical solution, the preparation method, wherein the preparation method of the second intermediate comprises:
[0024] The first intermediate, 1,2,4,5-benzenetetraamine tetrahydrochloride and potassium carbonate aqueous solution are dispersed in ethanol, and stirred at a temperature of 75-95° C. under the protection of inert gas to obtain the second intermediate; the structural formula of the first intermediate is
[0025] As a preferred technical solution, the preparation method, wherein the molar ratio of the first intermediate, 1,2,4,5-benzenetetraamine tetrahydrochloride and potassium carbonate is 4:3-4:7.2.
[0026] As a preferred technical solution, the preparation method, wherein the preparation method of the first intermediate comprises:
[0027] Under the protection of inert gas, triphenylamine is dissolved in anhydrous dichloromethane, anhydrous aluminum chloride is added and stirred to obtain a reaction solution;
[0028] The temperature of the reaction solution was maintained at 0° C., and oxalyl chloride was added dropwise to the reaction solution to obtain the first intermediate.
[0029] As a preferred technical solution, in the preparation method, the molar ratio of triphenylamine, anhydrous aluminum chloride and oxalyl chloride is 2-3:1:1.
[0030] The third party is a method for preparing the compound of formula I described in the first aspect, wherein R1 and R2 are The preparation method comprises the following steps:
[0031] Dispersing the first intermediate and 1,2,4,5-benzenetetraamine tetrahydrochloride in a mixed solution of toluene and pyridine, and stirring at 20° C. under inert gas protection to obtain compound PQ-L3;
[0032] The structural formula of the first intermediate is
[0033] The structural formula of the compound PQ-L3 is
[0034]
[0035] In a fourth aspect, a method for preparing the compound of formula II as claimed in claim 1, wherein R1 is The preparation method comprises the following steps:
[0036] The third intermediate and N-bromosuccinimide are dispersed in a mixed solution of dimethylformamide and acetic acid, and the reaction mixture is stirred at 50-70° C. under inert gas protection; the solvent in the reaction mixture is removed, the residue is dissolved in toluene, 4-boric acid triphenylamine, tetrakis(triphenylphosphine)palladium and potassium carbonate aqueous solution are added, and the mixture is stirred at 110-130° C. under inert gas protection to obtain compound PQ-L2;
[0037] The structural formula of the third intermediate is:
[0038]
[0039] The structural formula of PQ-L2 is:
[0040]
[0041] In a fourth aspect, a use of the aggregation-induced emission material with multi-photon absorption properties described in the first aspect in multi-photon fluorescence imaging.
[0042] Beneficial effect: Compared with the prior art, the present invention is based on the aggregation-induced luminescence molecule with multi-photon absorption properties constructed based on the pyrazine [2,3-g] quinoxaline structural unit, and the molecule has a strong intramolecular charge transfer characteristic. Triphenylamine as an electron donor has a large absorption cross section, so that the material has the property of multi-photon absorption. The molecule has strong absorption and high quantum yield in the wavelength range of 400-700nm, and shows good photodynamic activity. The molecule has the characteristics of simple structure, easy modification, adjustable performance, and easy preparation, and has good application prospects in multi-photon fluorescence imaging.
[0043] Based on the same inventive concept, the present invention provides a method for preparing the compound represented by formula I, comprising the following steps:
[0044]
[0045] Specifically, (1) Synthesis of intermediate 1: triphenylamine was dissolved in anhydrous dichloromethane under nitrogen protection at 0°C, and anhydrous aluminum chloride was added and the solution was stirred. Oxalyl chloride was added dropwise while the temperature of the reaction system was kept at 0°C, and stirred at room temperature for 6 hours. The molar ratio of triphenylamine, anhydrous aluminum chloride and oxalyl chloride was 3:1:1, and dichloromethane (200 ml) was used.
[0046] (2) Synthesis of intermediate 2: Add intermediate 1, 1,2,4,5-benzenetetramine tetrahydrochloride and potassium carbonate aqueous solution to ethanol at room temperature, and stir at 85°C under nitrogen protection for 12 hours. The molar ratio of intermediate 1, 1,2,4,5-benzenetetramine tetrahydrochloride and potassium carbonate is 4:3.7:7.2, ethanol (100 ml), water (5 ml).
[0047] (3) Synthesis of compound PQ-L1: Add intermediate 2 to acetic acid and dichloromethane at room temperature, add glyoxal to the stirred solution. Stir the reaction mixture under reflux for 6 hours under nitrogen protection. The molar ratio of intermediate 2 to glyoxal is 1:2, acetic acid (20 ml), and dichloromethane (10 ml).
[0048] (4) Synthesis of compound PQ-L3: Add intermediate 1 and 1,2,4,5-benzenetetraamine tetrahydrochloride to freshly evaporated toluene and pyridine solution at room temperature, and stir for 48 hours under nitrogen protection at 20°C. The molar ratio of intermediate 1 to 1,2,4,5-benzenetetraamine tetrahydrochloride is 2-4:1, toluene (25 ml), pyridine (10 ml).
[0049] (5) Synthesis of compound PQ-L4: Compound PQ-L3 and N-bromosuccinimide were added to dichloromethane at room temperature, and acetic acid was added dropwise to the stirred solution. The reaction mixture was stirred at room temperature for 0.5-2 hours. After removing the solvent, the residue was dissolved in freshly distilled toluene, and 4-boric acid triphenylamine, tetrakis(triphenylphosphine)palladium and potassium carbonate aqueous solution were added, and stirred at 120°C under nitrogen protection for 24 hours. The molar ratio of compound PQ-L3, N-bromosuccinimide, 4-boric acid triphenylamine, tetrakis(triphenylphosphine)palladium and potassium carbonate was 1:1.01:2.5:0.1:4, dichloromethane (25 ml), 3-5 drops of acetic acid, toluene (30 ml), water (1 ml).
[0050] Furthermore, the present invention also provides a method for preparing the compound represented by formula II, comprising the following steps:
[0051]
[0052] Specifically, (6) Synthesis of Intermediate 3: Add 1,2,4,5-benzenetetramine tetrahydrochloride, sodium acetate and glyoxal to an ethanol solution at room temperature, and reflux and stir for 0.5-1h under nitrogen protection. The molar ratio of 1,2,4,5-benzenetetramine tetrahydrochloride, sodium acetate and glyoxal is 1:4:3, ethanol (50ml), water (5ml).
[0053] (7) Synthesis of compound PQ-L2: Add intermediate 3 and N-bromosuccinimide to dimethylformamide and acetic acid solution at room temperature, and stir the reaction mixture for 16 hours under nitrogen protection at 60°C. Remove the solvent, dissolve the residue with freshly distilled toluene, add 4-triphenylamine borate, tetrakis(triphenylphosphine)palladium and potassium carbonate aqueous solution, and stir for 24 hours under nitrogen protection at 120°C. The molar ratio of intermediate 3, N-bromosuccinimide, 4-triphenylamine borate, tetrakis(triphenylphosphine)palladium and potassium carbonate is 1:2.02:2.5:0.1:4, dimethylformamide (25 ml), 3-5 drops of acetic acid, toluene (30 ml), water (1 ml).
[0054] In the present invention, compared with two-photon microscopy, three-photon microscopy has the following advantages: (1) The three-photon excitation wavelength of commonly used fluorescent proteins is longer, usually 1600-1800nm, which is in the best infrared light window of biological tissues and has better penetration effect in biological tissues; (2) As a higher-order nonlinear imaging method, three-photon microscopy not only has the optical sectioning ability of two-photon microscopy, but also has better background signal suppression ability than two-photon microscopy. Four-photon microscopy has the following advantages: (1) Four-photon fluorescence imaging can achieve deeper tissue imaging because the laser wavelength used is longer and has stronger ability to penetrate tissues; (2) Four-photon imaging technology has higher spatial resolution; (3) Because the laser power used is low, four-photon imaging causes less damage to tissues and is suitable for long-term living cell imaging. BRIEF DESCRIPTION OF THE DRAWINGS
[0055] Figure 1 is the hydrogen nuclear magnetic resonance spectrum of the first intermediate molecule prepared in Example 1 of the present invention in deuterated dimethyl sulfoxide;
[0056] Figure 2 is the hydrogen nuclear magnetic resonance spectrum of the second intermediate molecule prepared in Example 2 of the present invention in deuterated dichloromethane;
[0057] Figure 3 is a hydrogen nuclear magnetic resonance spectrum of the compound PQ-L1 molecule prepared in Example 3 of the present invention in deuterated dichloromethane;
[0058] Figure 4 is the carbon nuclear magnetic resonance spectrum of the compound PQ-L1 molecule prepared in Example 3 of the present invention in deuterated dichloromethane;
[0059] Figure 5 is a hydrogen nuclear magnetic resonance spectrum of the compound PQ-L3 molecule prepared in Example 4 of the present invention in deuterated dichloromethane;
[0060] Figure 6 is the carbon nuclear magnetic resonance spectrum of the compound PQ-L3 molecule prepared in Example 4 of the present invention in deuterated dichloromethane;
[0061] Figure 7 is a hydrogen nuclear magnetic resonance spectrum of the compound PQ-L4 molecule prepared in Example 5 of the present invention in deuterated dichloromethane;
[0062] Figure 8 is the carbon nuclear magnetic resonance spectrum of the compound PQ-L4 molecule prepared in Example 5 of the present invention in deuterated dichloromethane;
[0063] Fig. 9 is the hydrogen nuclear magnetic resonance spectrum of the third intermediate molecule prepared in Example 6 of the present invention in deuterated dimethyl sulfoxide;
[0064] Fig.10 is the hydrogen nuclear magnetic resonance spectrum of the compound PQ-L2 molecule prepared in Example 7 of the present invention in deuterated dichloromethane;
[0065] Fig.11 is the carbon NMR spectrum of the compound PQ-L2 molecule prepared in Example 7 of the present invention in deuterated chloroform;
[0066] Fig.12 is the ultraviolet absorption spectra of PQ-L1, PQ-L2, PQ-L3 and PQ-L4 molecules prepared in the examples of the present invention in tetrahydrofuran;
[0067] Fig.13 : is the fluorescence emission spectra of PQ-L1, PQ-L2, PQ-L3 and PQ-L4 molecules prepared in the examples of the present invention in tetrahydrofuran;
[0068] Fig.14 is the fluorescence emission spectrum of the PQ-L4 molecule prepared in Example 5 of the present invention in a mixed solvent of tetrahydrofuran / water (V / V);
[0069] Fig.15 is a fluorescence intensity graph of the PQ-L4 molecule prepared in Example 5 of the present invention in a mixed solvent of tetrahydrofuran / water (V / V);
[0070] Fig.16 This is a graph showing the PQ-L4 molecule prepared in Example 5 of the present invention in the brain blood vessel imaging experiment of mice. Specific implementation plan
[0071] Example 1
[0072] Preparation of the first intermediate
[0073] Under nitrogen protection at 0℃, add magnet, dichloromethane (200ml), triphenylamine (7.35g, 0.03mol) and anhydrous aluminum chloride (1.33g, 0.01mol) to a clean two-necked bottle and stir the solution. Keep the temperature of the reaction system at 0℃ and add oxalyl chloride (1.26g, 0.01mol) dropwise, and stir at room temperature for 6h. Separate the organic layer with a separatory funnel, and then extract and purify the obtained organic layer with water and dichloromethane in turn to obtain an organic phase, add anhydrous sodium sulfate to the organic phase for drying, and remove the solvent from the dried organic phase by reduced pressure distillation to obtain a green powder product. Use petroleum ether / ethyl acetate as eluent (PE:EA=3:1, V:V), column chromatography to separate 2.77g of yellow solid, yield: 51%. 1H NMR (400MHz, DMSO) δ7.74 (d, J = 9.0Hz, 4H), 7.39-7.33 (t, J = 8.4Hz, 8H), 7.21-7.13 (m, 12H), 6.78 (d, J = 9.0Hz, 4H). Figure 1 shown.
[0074] Example 2
[0075] Preparation of the second intermediate
[0076] Add magnet, anhydrous ethanol (100 ml), intermediate 1 (2.17 g, 4 mmol), 1,2,4,5-benzenetetramine tetrahydrochloride (1.05 g, 3.7 mmol), potassium carbonate (1 g, 7.2 mmol) and water (5 ml) to a clean two-necked bottle, and stir at 85°C under nitrogen protection for 12 h. Then filter and dry to obtain 2.05 g of yellow solid. Yield: 86%. 1 H NMR (400MHz, CD2Cl2) δ7.37 (d, J = 8.7Hz, 4H), 7.27-723. (t, J = 6.4Hz, 8H), 7.21 (s, 2H), 7.10 (d, J = 6.4Hz, 8H), 7.05-7.00 (t, J = 7.7Hz, 4H), 6.98 (d, J = 7.2Hz, 4H), 4.03 (s, 4H). Figure 2 shown.
[0077] Example 3
[0078] Preparation of compound PQ-L1
[0079] Add a magnetic particle, acetic acid (20 ml), degassed dichloromethane (10 ml), intermediate 2 (0.64 g, 1 mmol), and glyoxal (0.11 g, 2 mmol) to a clean two-necked bottle, and reflux and stir the reaction mixture under nitrogen protection for 6 h. Then, neutralize the acetic acid with sodium bicarbonate, extract and purify the obtained organic layer with water and dichloromethane in turn to obtain an organic phase, add anhydrous sodium sulfate to the organic phase for drying, remove the solvent from the dried organic phase by reduced pressure distillation, use petroleum ether / dichloromethane as eluent (PE:DCM=1:2, V:V), and chromatographically purify to obtain 0.21 g of a brown-red solid. Yield: 31%. 1HNMR (500MHz, CD2Cl2) δ8.92 (s, 2H), 8.83. (s, 2H), 7.54 (d, J = 7.6Hz, 4H), 7.33-7.27 (t, J = 6.7Hz, 8H), 7.13 (d, J = 8.7Hz, 8H), 7.13-7.08 (t, J = 8.3Hz, 4H), 7.03 (d, J = 9.0Hz, 4H). Figure 3 shown.
[0080] 13 C NMR (126MHz, CD2Cl2) δ155.81, 149.83, 147.54, 176.13, 142.39, 140.69, 132.46, 131.60, 130.06, 129.16, 125.89, 124.42, 121.92. The NMR carbon spectrum is shown in Figure 4 shown.
[0081] Example 4
[0082] Preparation of compound PQ-L3
[0083] Add a magnetic particle to a clean two-necked bottle, freshly evaporated toluene (25 ml), pyridine (10 ml), intermediate 1 (1.63 g, 3 mmol), 1,2,4,5-benzene tetraamine tetrahydrochloride (0.17 g, 1 mmol), and reflux the reaction mixture under nitrogen protection at 20°C for 48 hours. Filter, extract and purify the obtained organic layer with water and dichloromethane in turn to obtain an organic phase, add anhydrous sodium sulfate to the organic phase for drying, remove the solvent from the dried organic phase by reduced pressure distillation, use petroleum ether / dichloromethane as eluent (PE:DCM=1:3, V:V), and chromatographically purify to obtain 0.42 g of a brown-red solid. Yield: 37%. 1 HNMR (500MHz, CD2Cl2) δ8.76 (s, 2H), 7.55. (d, J = 8.2Hz, 8H), 7.32-7.28 (t, J = 9.1Hz, 16H), 7.17-7.08 (m, 24H), 7.03 (d, J = 7.4Hz, 8H). Figure 5 shown.
[0084] 13 C NMR (126MHz, CD2Cl2) δ154.73, 149.20, 147.40, 140.48, 132.39, 131.15, 130.69, 126.57, 124.37, 123.89, 122.32. The NMR carbon spectrum is shown in Figure 6 shown.
[0085] Example 5
[0086] Preparation of compound PQ-L4
[0087] Add a magnetic particle, degassed dichloromethane (25 ml), compound PQ-L3 (115 mg, 0.1 mmol) and N-bromosuccinimide (19 mg, 0.11 mmol) to a clean two-necked bottle, and add 3 drops of acetic acid to the stirred solution. Stir the reaction mixture for 3 h under nitrogen protection at room temperature. Extract and purify the obtained organic layer with water and dichloromethane in turn to obtain an organic phase, add anhydrous sodium sulfate to the organic phase for drying, and remove the solvent from the dried organic phase by reduced pressure distillation to obtain 125 mg of a yellow solid. Yield: 96%. Dissolve the obtained yellow solid (131.02 mg, 0.1 mmol) in freshly distilled toluene (30 ml), add 4-boric acid triphenylamine (72 mg, 0.25 mmol), tetrakis(triphenylphosphine) palladium (11.55 mg, 0.01 mmol), potassium carbonate (55.28 mg, 0.4 mmol) and water (1 ml), and stir at 120 ° C under nitrogen protection for 24 h. The organic layer was filtered, extracted and purified with water and dichloromethane in turn to obtain an organic phase, anhydrous sodium sulfate was added to the organic phase for drying, the dried organic phase was distilled under reduced pressure to remove the solvent, and chromatographic purification was performed using petroleum ether / dichloromethane, dichloromethane as eluent (PE:DCM, DCM=1:2,1, V:V) to obtain 144 mg of purple-red solid. Yield: 88%. 1 H NMR (500MHz, CD2Cl2) δ7.79 (d, J = 8.4Hz, 4H), 7.59 (d, J = 9.0Hz, 8H), 7.32-7.27 (t, J = 9.2Hz, 16H), 7.26-7.19 (m, 20H), 7.17-7.08 (m, 24H), 6.99 (m, 12H). Figure 7 shown.
[0088] 13 C NMR (126MHz, CD2Cl2) δ152.51, 149.80, 148.51, 137.84, 135.93, 132.78, 131.77, 130.26, 126.16, 125.81, 125.23, 124.56, 121.98. The carbon NMR spectrum is shown in Figure 8 shown.
[0089] Example 6
[0090] Preparation of intermediate 3
[0091] Add a magnetic particle, anhydrous ethanol (50ml), water (5ml), 2,4,5-benzenetetramine tetrahydrochloride (1.74g, 0.01mol) and sodium acetate (3.28g, 0.04mol) to a clean two-necked bottle, stir at room temperature for 10min, then add glyoxal (2.32g, 0.04mol), and stir the reaction mixture at 75℃ for 6h. Concentrate the mixture, and add water (10ml) and saturated sodium bicarbonate (20ml) to the residue. Extract the mixture three times with ether (30ml), wash the organic phase three times with brine, and dry it with anhydrous sodium sulfate. After removing the solvent, use n-hexane / ethanol as eluent (HEX:EtOH=5:1,V:V) for chromatography purification to obtain 0.92g of yellow solid. Yield: 51%. 1 H NMR (500MHz, DMSO) δ9.10 (s, 4H), 8.86. (s, 2H). Fig. 9 shown.
[0092] Example 7
[0093] Preparation of compound PQ-L2
[0094] Add a magnetic bar, degassed DMF (25 ml), intermediate 3 (182 mg, 1 mmol) and N-bromosuccinimide (359.51 mg, 2.02 mmol) to a clean two-necked bottle, and add 3 drops of acetic acid to the stirred solution. Stir the reaction mixture for 16 h at 60 ° C under nitrogen protection. Cool the reaction mixture to 24 ° C, dilute with H2O (10 ml), and filter. Wash the precipitate with H2O (100 ml) and cold CH2Cl2 (100 ml). Dissolve the precipitate (168 mg, 0.5 mmol) with freshly distilled toluene, add 4-boric acid triphenylamine (578.24 mg, 2 mmol), tetrakis(triphenylphosphine)palladium (11.55 mg, 0.01 mmol), potassium carbonate (276 mg, 2 mmol) and water (2 ml), and stir at 120 ° C under nitrogen protection for 24 h. The organic layer was filtered, extracted and purified with water and dichloromethane in turn to obtain an organic phase, anhydrous sodium sulfate was added to the organic phase for drying, the dried organic phase was distilled under reduced pressure to remove the solvent, and chromatographic purification was performed using petroleum ether / dichloromethane, dichloromethane as eluent (PE:DCM, DCM=1:1,1, V:V) to obtain 220 mg of a purple-red solid. Yield: 64%. 1H NMR (500MHz, CD2Cl2) δ8.90 (s, 4H), 7.50 (d, J = 6.8Hz, 4H), 7.35-7.33 (t, J = 8.9Hz, 8H), 7.26 (d, J = 7.4Hz, 8H), 7.20 (m, 4H), 7.12-7.09 (t, J = 7.5Hz, 4H). Fig.10 shown.
[0095] 13 C NMR (126MHz, CDCl3) δ148.02, 147.82, 145.96, 143.59, 139.65, 134.11, 129.72, 127.46, 125.91, 123.87, 121.11. The NMR carbon spectrum is shown in Fig.11 shown.
[0096] Test Example 1
[0097] 1. Absorption, molar absorptivity and emission spectra:
[0098] PQ-L1, PQ-L2, PQ-L3 and PQ-L4 were dissolved in THF to prepare 10 μM, and UV absorption (Shimadzu UV-1600i) and fluorescence emission spectrum tests (Edinburgh fluorescence spectrometer) were performed. Fig.12 As shown, the absorption peaks of PQ-L1, PQ-L2, PQ-L3 and PQ-L4 are 478nm, 515nm, 520nm and 540nm respectively. Fig.13 As shown, the emission spectrum peaks of PQ-L1, PQ-L2, PQ-L3 and PQ-L4 are 650nm, 757nm, 658nm and 717nm respectively, and all four molecules have significant deep red and near-infrared emission properties.
[0099] Test Example 2
[0100] 2.AIE curve test:
[0101] Solutions of PQ-L1, PQ-L2, PQ-L3 and PQ-L4 (10 μM) in THF / water mixed solvents with water contents ranging from 0% to 99% were prepared and emission spectra were tested. Fig.14 As shown, the emission spectra of PQ-L1, PQ-L2, PQ-L3 and PQ-L4 molecules in solvents with different water contents are shown. Fig.15 This is the variation curve of the emission peak intensity at different water ratios.
[0102] Test Example 3
[0103] 3. In vivo deep brain imaging
[0104] A craniotomy was performed on anesthetized mice, with the center of the craniotomy located 2 mm posterior and lateral to the Bregma point, and a 5 mm diameter transparent glass slide was used to seal the mouse cranial window so that light could enter the mouse brain. PQ-L4 nanoparticles were injected into the mice via orbital injection, and the mice were imaged after injection. Imaging used a 1 MHz 1550 nm fiber laser (FLCPA-02CSZU, Calmar) as pump to generate 2200 nm frequency-shifted soliton pulses in a large mode area fiber. After long-pass filtering to remove residual pump, half-wave plates and polarization beam splitters to control the optical power, the soliton pulses were used for the laser scanning microscope of the MPM. Water immersion objectives were used for all imaging experiments, and image acquisition and processing were performed using ScanImage and ImageJ software, respectively, as shown in Figure 2. Fig.16 As shown, the imaging depth is at 650 nm.
[0105] It should be understood that the application of the present invention is not limited to the above examples. For ordinary technicians in this field, improvements or changes can be made based on the above description. All these improvements and changes should fall within the scope of protection of the claims attached to the present invention.
Claims
1. An aggregation-induced luminescence material having multiphoton absorption properties, characterized in that: The structural formula of the aggregation-induced emission material is shown in Formula I or Formula II: Wherein, R1 and R2 are independently expressed as:
2. The aggregation-induced emission material according to claim 1, characterized in that: The R1 and R2 are each independently represented by:
3. A method for preparing the compound of formula I as claimed in claim 1, characterized in that: The R1 is The R2 is The preparation method comprises the following steps: The second intermediate is mixed with ethanol and dichloromethane, glyoxal is added under stirring, and reflux treatment is performed in an inert gas atmosphere to obtain a reaction mixture; the structural formula of the second intermediate is Neutralizing the acetic acid in the reaction mixture, and performing an extraction operation with an extractant to obtain an organic phase; The solvent in the organic phase is removed to obtain compound PQ-L1; the structural formula of the compound PQ-L1 is 4. The preparation method according to claim 3, characterized in that: The preparation method of the second intermediate comprises: The first intermediate, 1,2,4,5-benzenetetraamine tetrahydrochloride and potassium carbonate aqueous solution are dispersed in ethanol, and stirred at a temperature of 75-95° C. under the protection of inert gas to obtain the second intermediate; the structural formula of the first intermediate is 5. The preparation method according to claim 4, characterized in that: The molar ratio of the first intermediate, 1,2,4,5-benzenetetraamine tetrahydrochloride and potassium carbonate is 4:3-4:7.
2.
6. The preparation method according to claim 4, characterized in that: The preparation method of the first intermediate comprises: Under the protection of inert gas, triphenylamine is dissolved in anhydrous dichloromethane, anhydrous aluminum chloride is added and stirred to obtain a reaction solution; The temperature of the reaction solution was maintained at 0° C., and oxalyl chloride was added dropwise to the reaction solution to obtain the first intermediate.
7. The preparation method according to claim 6, characterized in that: The molar ratio of triphenylamine, anhydrous aluminum chloride and oxalyl chloride is 2-3:1:
1.
8. A method for preparing the compound of formula I as claimed in claim 1, characterized in that: R1 and R2 are The preparation method comprises the following steps: The first intermediate and 1,2,4,5-benzenetetraamine tetrahydrochloride are dispersed in a mixed solution of toluene and pyridine, and stirred under inert gas protection at a temperature of 20° C. to obtain compound PQ-L3; the structural formula of the first intermediate is The structural formula of the compound PQ-L3 is 9. A method for preparing the compound of formula II as claimed in claim 1, characterized in that: The R1 is The preparation method comprises the following steps: Dispersing the third intermediate and N-bromosuccinimide in a mixed solution of dimethylformamide and acetic acid, and stirring the reaction mixture under an inert gas protection condition at 50-70° C.; The solvent in the reaction mixture is removed, the residue is dissolved in toluene, 4-boric acid triphenylamine, tetrakis(triphenylphosphine)palladium and potassium carbonate aqueous solution are added, and the mixture is stirred at 110-130° C. under inert gas protection to obtain compound PQ-L2; The structural formula of the third intermediate is: The structural formula of PQ-L2 is:
10. Use of the aggregation-induced emission material having multiphoton absorption properties as claimed in claim 1 in multiphoton fluorescence imaging.
Citation Information
Patent Citations
Derivative containing azaanthracene structure, preparation method of derivative and organic light-emitting device comprising derivative
CN107805243A
OLED material containing naphthophenanthridine structure, and applications thereof
CN108358922A
Heterocyclic compound, and organic electroluminescence device and organic electroluminescence display device including same
CN109535160A
Organic photosensitizer on basis of pyrazine [2,3-g] quinoxaline, method for preparing organic photosensitizer and photodynamic application thereof
CN109734721A
Preparation, electrochemical polymerization and application of Y-type conjugated monomer
CN116265419A
Cited By
Organic electroluminescent material based on pyrazine derivative and preparation method and application thereof
CN119930613A
